Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50911 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL14889462 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL253323 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11645490 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL9360142 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL7673902 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11882526 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11771376 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11882927 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL8131815 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR2 340/4885DPP4 352/4885EBP 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.